Document:

<PAGE>

                                                                  Exhibit 10.5

MYMETICS ANNOUNCES ENCOURAGING PRECLINICAL RESULTS OF THE COMPANY'S HIV VACCINE
CANDIDATE IN NON-HUMAN PRIMATES

STUDY CONFIRMS ABILITY OF VACCINE CANDIDATE TO ELICIT ANTI-GP41 ANTIBODIES

PHASE I HUMAN CLINICAL TRIAL PLANNED BY THE END OF 2007

Nyon (Switzerland), June 21, 2006 -- Mymetics Corporation (Nasdaq OTC.PK:
MYMX.PK) announced today encouraging, preliminary findings from non-human
primate preclinical studies of the Company's HIV-AIDS prophylactic vaccine
candidate. Analysis of blood samples taken six weeks post-vaccination with
virosome-gp41 peptides have revealed the presence of anti-gp41 antibodies (IgG
and IgA), confirming previous data from rabbit models. The immunization
protocols will continue through early September 2006 in order to detect the
production of secretory IgA antibodies in mucosal tissues, the primary route of
infection and a first line of defense against HIV.

Dr. Sylvain Fleury, Ph.D., Mymetics' Chief Scientific Officer, commented, "At
the mid-point of our non-human primate trials, we are greatly encouraged by the
results, particularly in the ability to trigger protective antibodies against
gp41 independently from gp120, another key target in HIV. Based on the current
timeline, we hope to be able to detect the presence of mucosal antibodies by the
end of the third quarter, following which we will seek to demonstrate protection
against HIV infection in these animal models by the first quarter of 2007. Our
ultimate goal is to initiate Phase I human clinical trials by the end of 2007,
pending the positive preclinical results."

Mymetics' vaccine candidate combines the Company's HIV-1 gp41-derived peptide
antigen grafted onto biosynthetic spherical lipidic structures called virosomes,
which are approved for human use. Previous Company research has demonstrated
that virosome-based vaccine technology is able to elicit protective antibodies
in various anatomical compartments, which may prevent viral translocation across
mucosal tissues and infection of blood cells by different HIV clades (genetic
sub-groups). These virosomes mimic the HIV envelope and allow proper viral
peptide/protein and epitope orientations, similar to what is found on native
HIV.

Underlying these efforts is Mymetics' key discovery of a fundamental though
subtle three-dimensional mimicry between the viral envelope glycoprotein gp41 of
HIV-1 and the IL-2 cytokine (Interleukin-2) of the infected host. Mymetics
strongly believes that it is crucial to prevent the potential induction of
cross-reactivity toward self-proteins, such as IL-2, post-vaccination in order
to generate a protective and long-lasting mucosal immune response against HIV-1.

MUCOSAL APPROACH

Worldwide, over 85% of HIV infections are the result of sexual transmission in
which mucosal tissues from the genital and anorectal regions have been exposed
to HIV-1 present in semen or secretions. Mymetics is developing a vaccine
technology that elicits protective antibodies in various anatomical
compartments, such as blood, but most importantly in mucosal tissues within the
genital and intestinal tracts, particularly via secretory IgA antibodies.

<PAGE>

Results presented earlier this year at the Keystone Symposium on HIV
Pathogenesis have demonstrated that sequential, intranasal immunizations of
Mymetics' vaccine candidate in a rabbit model led to a sustained mucosal immune
antibody response, both in the vaginal and intestinal tracts, which lasted at
least 2 months after the last injection. A similar immune response may be
obtained using the intramuscular route only, thereby avoiding the need for a
mucosal adjuvant. The Company is currently investigating in non-human primates
whether intramuscular injections alone can match the levels of mucosal
antibodies achieved following sequential intranasal and intramuscular
injections. Final results are expected for September 2006.

In previous in vitro studies, Mymetics-affiliated researchers demonstrated that
mucosal antibodies (vaginal and intestinal) were highly potent in inhibiting
transcytosis of laboratory and primary HIV viruses from different clades,
including the B clade, common in North & South America and Western Europe, and
the C clade, which is found in South Africa, India and parts of China and
accounts for more than 60% of cases of HIV infection. The overall inhibition
capacity varied from 70% to 95%. In addition, ELISA tests demonstrated that the
mucosal antibodies were dominantly constituted of monomeric IgG and dimeric
secretory IgA. Vaginal secretions containing antibodies were also very potent in
inhibiting primary macrophage infections (>90%). Additional studies will be
performed to investigate dendritic and T cell infection.

MYMETICS' HIV VACCINE PROGRAM

Mymetics' innovative AIDS vaccine proposes an approach that could prevent HIV
entry at the mucosal level (primary entry: early event) as well as preventing
cell infection by HIV (late event). To achieve this goal, Mymetics has combined
three important concepts in the vaccine design: 1- Induction of mucosal and
blood antibodies to allow protection in different anatomical compartments and
block the early event of HIV translocation at the genito-reproductive and
intestine tracts and subsequent infection of target cells underlying the mucosal
tissues, thereby preventing HIV entry and spreading in the body. 2- Focusing the
immune response against conserved regions on gp41 that may induce protective
antibodies against a broad range of HIV clades. Mymetics is developing vaccines
that contain antigens expressing limited immunodominant regions, while
immunodistractive regions have been removed or altered without affecting the
immunogenicity of the antigen. 3- Minimal mimicry. In this approach, Mymetics
uses a small engineered HIV protein sequence from gp41, which has been deleted
of its human protein homologies. The Company's approach is designed to
significantly reduce the risk of developing potential autoimmunity on a
long-term basis following vaccination.

Mymetics believes that it is pioneering an innovative and efficient research
strategy. Instead of incurring high fixed costs to maintain its own staff and
research facilities, Mymetics organizes and manages a network of public and
private research teams that it believes are best-in-class, each of which has its
own particular focus, while the Company retains all intellectual property rights
to the joint research results.

ABOUT MYMETICS

Mymetics was founded in 1990 near Lyon, France and was registered as a US
(Delaware) public company in 2000. Since August 2003, its operations and
research programs have been managed out of Switzerland (Nyon, near Geneva).

<PAGE>

Mymetics Common shares trade on NASDAQ's OTC:PK under the symbol MYMX.

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements that involve risks and
uncertainties. The statements contained in this report that are not purely
historical are forward-looking statements within the meaning of Section 21E of
the Securities Exchange Act of 1934, as amended, and Section 27A of the
Securities Act of 1933, as amended. These forward looking statements concern
matters that involve risks and uncertainties that could cause actual results to
differ materially from those stated in the forward-looking statements. Words
such as "may," "will," "should," "could," "expect," "plan," "anticipate,"
"believe," "estimate," "predict," "potential", "continue", "possibly",
"clearly", "encouraging", "promising" or similar words are intended to identify
forward looking statements, although not all forward looking statements contain
these words. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results,
levels of activity performance or achievements. Moreover, neither we nor any
other person assumes responsibility for the accuracy and completeness of the
forward-looking statements. We are under no duty to update any of the
forward-looking statements after the date hereof to conform such statements to
actual results or to changes in our expectations. Readers are urged to carefully
review and consider the various disclosures made by us which attempt to advise
interested parties of the factors which affect our business, including without
limitation disclosures made under the captions "Management Discussion and
Analysis of Financial Condition and Results of Operations," "Risk Factors,"
"Consolidated Financial Statements" and "Notes to Consolidated Financial
Statements" included in the Company's annual report on Form 10-K for the year
ended December 31, 2005.

CONTACT: Ernest Luebke, CFO, Mymetics Corp., +41-22-363-1310,
eluebke@mymetics.comEX-10.1

 

Exhibit 10.1

STANDBY TERM LOAN NOTE

	 	 	 
	 

	 	August 16, 2006
	$30,000,000.00

	 	Pittsburgh, Pennsylvania

     For value received, SUPERIOR WELL SERVICES, INC., a Delaware corporation, SUPERIOR WELL
SERVICES, LTD., a Pennsylvania limited partnership, and BRADFORD RESOURCES, LTD., a Pennsylvania
limited partnership, jointly and severally promise to pay to the order of CITIZENS BANK OF
PENNSYLVANIA, a Pennsylvania state chartered bank (the “Lender”), at the Lender’s Office,
on or before the Standby Term Loan Maturity Date, the lesser of (i) the principal sum of THIRTY
MILLION DOLLARS ($30,000,000.00), or (ii) at all times prior to the Standby Term Loan Conversion
Date, the unpaid principal amount of the Standby Term Loan Advances made by the Lender to the
Borrowers pursuant to that certain Credit Agreement dated as of October 18, 2005 among the
Borrowers and the Lender, as amended by that certain First Amendment to Credit Agreement of even
date herewith among the Borrowers and the Lender (as so amended, and as the same may be further
modified or otherwise further amended from time to time, the “Credit Agreement”), and at
all times after the Standby Term Loan Conversion Date, the unpaid principal amount of the Standby
Term Loan. The Borrowers promise to pay to the order of the Lender interest on the unpaid
principal amount of this Note from time to time outstanding from the date hereof until all amounts
due hereunder are paid, at the rate or rates per annum provided for in the Credit Agreement with
respect to the Standby Term Loan Advances or the Standby Term Loan, as applicable. All payments of
principal and interest under this Note shall be made in accordance with, and at the times required
by, the provisions of the Credit Agreement with respect to the Standby Term Loan Advances or the
Standby Term Loan, as applicable. All capitalized terms used herein shall, unless otherwise
defined herein, have the same meanings assigned to such terms in the Credit Agreement.

     This Note is the “Standby Term Loan Note” referred to in, and evidences certain indebtedness
incurred under, the Credit Agreement to which reference is made for a statement of the terms and
provisions thereof, including those under which such indebtedness may be declared to be immediately
due and payable. This Note is secured by and entitled to the benefits of, inter alia, the
Credit Agreement and the Collateral Documents.

     The following paragraph sets forth a warrant of authority for an attorney to confess
judgment against the Borrowers, jointly and severally. In granting this warrant to confess
judgment against the Borrowers, the Borrowers hereby knowingly, intentionally, voluntarily and, on
the advice of separate counsel of the Borrowers, unconditionally waive any and all rights the
Borrowers have or may have to prior notice and an opportunity for hearing before a judgment can be
entered hereunder:

     THE BORROWERS UNCONDITIONALLY AND IRREVOCABLY AUTHORIZE AND EMPOWER ANY ATTORNEY OR ANY
PROTHONOTARY, CLERK OF COURT OR COURT OF RECORD, AS ATTORNEY FOR THE BORROWERS, TO APPEAR FOR THE
BORROWERS IN SUCH COURT AT ANY TIME AFTER THE OCCURRENCE OF AN EVENT OF DEFAULT UNDER THE CREDIT
AGREEMENT AND CONFESS JUDGMENT AGAINST THE BORROWERS, JOINTLY AND SEVERALLY, IN FAVOR OF THE LENDER
FOR ALL OR ANY PORTION OF THE OUTSTANDING PRINCIPAL BALANCE OF THIS NOTE, TOGETHER WITH UNPAID
INTEREST, COSTS OF SUIT AND ATTORNEYS’ FEES ADDED FOR COLLECTION IN AN AMOUNT EQUAL TO THE GREATER
OF FIVE PERCENT (5.0%) OF THE SUM DUE OR $15,000.00. THE BORROWERS ALSO RELEASE ALL ERRORS, AND TO
THE EXTENT PERMITTED BY LAW, WAIVE AND RELEASE ALL RELIEF FROM ANY AND ALL APPRAISEMENT, STAY OR
EXEMPTION LAW OF ANY STATE NOW IN FORCE OR HEREAFTER ENACTED. IF A COPY OF THIS NOTE, VERIFIED BY
AFFIDAVIT OF THE LENDER OR SOMEONE ON BEHALF OF THE LENDER, SHALL HAVE BEEN FILED IN SUCH ACTION,
IT SHALL NOT BE NECESSARY TO FILE AN ORIGINAL OF THIS

 

 

NOTE AS A WARRANT OF ATTORNEY. THE AUTHORITY AND POWER TO APPEAR FOR AND ENTER JUDGMENT AGAINST
THE BORROWERS SHALL NOT BE EXHAUSTED BY THE INITIAL EXERCISE THEREOF OR BY ANY IMPERFECT EXERCISE
THEREOF AND SHALL NOT BE EXTINGUISHED BY ANY JUDGMENT ENTERED PURSUANT THERETO; THE AUTHORITY AND
POWER MAY BE EXERCISED ON ONE OR MORE OCCASIONS, FROM TIME TO TIME, IN THE SAME OR DIFFERENT
JURISDICTIONS, AS OFTEN AS THE LENDER SHALL DEEM NECESSARY OR DESIRABLE, FOR ALL OF WHICH THIS NOTE
OR A VERIFIED COPY HEREOF SHALL BE A SUFFICIENT WARRANT. TO THE EXTENT PERMITTED BY LAW, INTEREST
SHALL ACCRUE ON ANY JUDGMENT AT THE DEFAULT RATE PROVIDED FOR IN SECTION 3.01(d)(iii) OF THE CREDIT
AGREEMENT TO ACCRUE ON PRIME RATE TRANCHES UPON THE OCCURRENCE OF AN EVENT OF DEFAULT UNDER THE
CREDIT AGREEMENT.

     The Borrowers hereby expressly waive presentment, demand, notice, protest and all other
demands and notices in connection with the delivery, acceptance, performance, default or
enforcement of this Note. In any action on this Note, the Lender need not produce or file the
original of this Note, but need only produce or file a photocopy hereof certified by the Lender to
be a true and correct copy hereof.

     THE BORROWERS HEREBY EXPRESSLY WAIVE ANY RIGHT TO TRIAL BY JURY OR ANY CLAIM, DEMAND, ACTION
OR CAUSE OF ACTION (i) ARISING UNDER THIS NOTE, OR (ii) IN ANY WAY CONNECTED WITH OR RELATED OR
INCIDENTAL TO THE DEALINGS OF THE BORROWERS WITH RESPECT TO THIS NOTE, OR THE TRANSACTIONS RELATED
HERETO, IN EACH CASE WHETHER SOUNDING IN CONTRACT OR TORT OR OTHERWISE; AND THE BORROWERS HEREBY
AGREE AND CONSENT THAT ANY SUCH CLAIM, DEMAND, ACTION OR CAUSE OF ACTION SHALL BE DECIDED BY COURT
TRIAL WITHOUT A JURY, AND THAT THE LENDER MAY FILE AN ORIGINAL COUNTERPART OR A COPY OF THIS NOTE
WITH ANY COURT AS WRITTEN EVIDENCE OF THE CONSENT OF THE BORROWERS TO THE WAIVER OF THEIR RIGHT TO
TRIAL BY JURY.

     All obligations of the Borrowers hereunder are joint and several, absolute and unconditional,
and shall bind their respective successors and assigns.

     This Note is intended as an instrument under seal and shall be governed by, and construed and
enforced in accordance with, the Laws of the Commonwealth of Pennsylvania, excluding its rules
relating to the conflict of laws.

******SIGNATURES APPEAR ON THE FOLLOWING PAGE******

2

 

     IN WITNESS WHEREOF, and intending to be legally bound hereby, the Borrower has executed this
Standby Term Loan Note the day and year first above written.

	 	 	 	 	 	 	 	 	 
	 	 	SUPERIOR WELL SERVICES, INC.	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	By:	 	/s/ Thomas W. Stoelk	 	 
	 	 	 	 	 	 	 
	 

	 	Title:	 	Vice President & Chief
Financial Officer	 	 
	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	SUPERIOR WELL SERVICES, LTD.	 	 
	 	 	By:	 	Superior GP, L.L.C., Its sole general partner	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	/s/ Thomas W. Stoelk 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	Title:	 	Vice President & Chief
Financial Officer 	 	 
	 

	 	 	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	 	 	BRADFORD RESOURCES, LTD.	 	 
	 	 	By:	 	Superior GP, L.L.C., Its sole general partner	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	By:	 	/s/ Thomas W. Stoelk 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	Title:	 	Vice President & Chief
Financial Officer 	 	 
	 

	 	 	 	 	 	 	 	 

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00109-of-00352.parquet"}]]